2020
Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC)
Luna A, Wu Q, Hlady R, Sathyanarayan A, Rustgi V, Guarrera J, Robertson K, Liu C. Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC). The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.08693.Peer-Reviewed Original ResearchHepatocellular carcinomaCancer risk detectionInhibitor 5-aza-2'-deoxycytidineHepatocellular carcinoma detectionHepatocellular carcinoma patientsEpigenetic changesHepatocellular carcinoma tumorsHuh7.5 cellsImproved treatment optionsHCC cell linesGene promoter sitesStressed cellsTreatment optionsTumor formationEpigenetic disruptionEffective treatmentGenetic mutationsLiver cancerEpigenetic dysregulationTumorMethylation inhibitorSuppressor of hepatocellular carcinomaTumor pathwaysWestern blot showEpigenetic events
2012
Glypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy
Trinh T, Liu C. Glypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy. The FASEB Journal 2012, 26: 405.1-405.1. DOI: 10.1096/fasebj.26.1_supplement.405.1.Peer-Reviewed Original ResearchHCC cell linesDifferent HCC cell linesGlypican-3Hepatocellular carcinomaTherapeutic targetCell linesNon-tumor liver tissuesHepatocellular Carcinoma ImmunotherapyCell proliferationNovel therapeutic targetPotential therapeutic targetCancer cell proliferationInhibited cell proliferationDose-dependent mannerAnti-GPC3 antibodiesHuman HCC tissuesNormal primary hepatocytesHCC immunotherapyCell surface heparinGPC3 expressionHCC tissuesLiver tissueImmunotherapyWestern blotHuman tumors
2011
Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells
Zhao X, Ogunwobi O, Liu C. Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells. PLOS ONE 2011, 6: e21980. PMID: 21829603, PMCID: PMC3148218, DOI: 10.1371/journal.pone.0021980.Peer-Reviewed Original ResearchConceptsBcl-2 inhibitorsCombination treatmentHCC cellsABT-263Survivin inhibitionHepatocellular carcinomaHuman liver cancer tissuesSingle treatmentFuture clinical trialsApoptotic effectsLiver cancer tissuesLiver cancer therapyERK activationHCC cell linesHepatocellular carcinoma cellsPreclinical dataClinical trialsTherapeutic effectLow doseNormal human hepatocytesCancer tissuesYM-155High dosesNovel Bcl-2 inhibitorABT-263-induced apoptosisEpigenetic regulation of homeobox genes in liver cancer
Liu H, Robertson K, Liu C. Epigenetic regulation of homeobox genes in liver cancer. The FASEB Journal 2011, 25: 794.12-794.12. DOI: 10.1096/fasebj.25.1_supplement.794.12.Peer-Reviewed Original ResearchHox genesEpigenetic regulationHomeobox genesAmino acid DNA-binding domainHox gene regulationDNA-binding domainHox gene familyHCC cell linesBp DNA sequenceCell linesGene familyGene regulationEpigenetic modificationsEpigenetic mechanismsIdentity of cellsTranscription factorsDNA sequencesTrichostatin A.Expression profilesCancer tissuesDifferential expressionGenesCell line experimentsNormal developmentHCC cancer tissues
2007
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson D. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells. Laboratory Investigation 2007, 87: 582-590. PMID: 17372588, DOI: 10.1038/labinvest.3700540.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsRegulatory T cellsT cell proliferationT cellsCancer patientsControl peripheral blood mononuclear cellsDepletion of TregsAntigen-reactive lymphocytesTumor-related factorsBlood mononuclear cellsHepatocellular carcinoma patientsT cell populationsHost immune systemCell linesSuppressor abilityHCC cell linesHuman hepatoma cell lineAntitumor immunityCarcinoma patientsTumor burdenFoxp3 expressionMononuclear cellsCTLA-4Reactive lymphocytesTregs